DrugPatentWatch Database Preview

Details for Patent: 10,272,046

« Back to Dashboard

Which drugs does patent 10,272,046 protect, and when does it expire?

Patent 10,272,046 protects KALYDECO and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 10,272,046

Title:	Pharmaceutical composition and administrations thereof
Abstract:	The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.
Inventor(s):	Dokou; Eleni (Cambridge, MA), Jamzad; Shahla (Belmont, MA), Caesar, Jr.; John P. (Lancaster, MA), Fawaz; Majed (Foxboro, MA), Das; Laura (Charlestown, MA), Gu; Chong-Hui (Waban, MA), Hurter; Patricia Nell (Harvard, MA), Israni; Meghna Jai (Boston, MA), Johnston; Meghan M. (Wakefield, MA), Knezic; Dragutin (Watertown, MA), Kuzmission; Andrew G. (Shrewsburg, MA), Wang; HongRen (Lexington, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:	15/181,114
Prior Art and Litigation Support	Order Prior Art and Litigation support for Patent 10,272,046
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 10,272,046

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-003	Apr 29, 2019		RX	Yes	No			Y			TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-001	Mar 17, 2015		RX	Yes	No			Y			TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO
Vertex Pharms Inc	KALYDECO	ivacaftor	GRANULE;ORAL	207925-002	Mar 17, 2015		RX	Yes	Yes			Y			TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO

International Family Members for US Patent 10,272,046

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013226076
Canada	2865519
China	104470518